News & Events

Disc Medicine Appoints Will Savage, MD, PhD as Chief Medical Officer and Jonathan Yu as Chief Business Officer and Expands Scientific Leadership with Key Hires to Advance Clinical-Stage Pipeline

Company welcomes Dr. Hua Yang, PhD, as VP, Nonclinical Development and Clinical Pharmacology and Sarah Tuller, JD as VP, Regulatory Affairs CAMBRIDGE, Mass. (August 23, 2021) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for

More News

Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed...

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

Facility significantly increases future financial and operational flexibility Up to $200M available, with $30 million drawn at close and additional $80 million...

Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

Oral presentation of complete data from Phase 1b trial of DISC-0974 in anemia of myelofibrosis (MF) Poster presentations across all programs, including...